AvalehtGNLX • NASDAQ
add
Genelux Corp
Viimane sulgemishind
2,58 $
Aasta vahemik
1,60 $ - 13,97 $
Turuväärtus
89,11 mln USD
Keskmine maht
114,55 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 6,94 mln | 30,79% |
Puhastulu | −6,47 mln | −20,99% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −0,19 | 5,00% |
EBITDA | −6,88 mln | −33,07% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 34,06 mln | 14,02% |
Kogu vara | 40,27 mln | 18,19% |
Kõik kohustused | 7,18 mln | −28,52% |
Kogu omakapital | 33,09 mln | — |
Emiteeritud aktsiate arv | 34,10 mln | — |
Hinna ja väärtuse suhe P/B | 2,66 | — |
Varade tasuvus | −40,61% | — |
Kapitali tasuvus | −46,27% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −6,47 mln | −20,99% |
Põhitegevuse rahakäive | −5,75 mln | −71,22% |
Investeeringute raha | 3,99 mln | 1 541,16% |
Finantseerimise raha | 0,00 | −100,00% |
Raha ja raha ekvivalentide muutus | −1,76 mln | −164,35% |
Tasuta rahavoog | −3,23 mln | −117,71% |
Teave
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Asutatud
2001
Veebisait
Töötajate arv
25
